Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter.
about
Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug ResistanceBile acids alter the subcellular localization of CNT2 (concentrative nucleoside cotransporter) and increase CNT2-related transport activity in liver parenchymal cellsXenobiotic, bile acid, and cholesterol transporters: function and regulation.Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC-MS/MS quantification.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.Host-based ribavirin resistance influences hepatitis C virus replication and treatment response.Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infectionTelaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(-/-) mice.Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice.Role of ribavirin in HCV treatment response: now and in the future.Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition.Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes.Pharmacogenetics of ribavirin-induced anemia in hepatitis C.The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouse.Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.Inhibition of warfarin activity by ribavirin.Effect of dietary purines on the pharmacokinetics of orally administered ribavirin.Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta
P2860
Q24594939-5655EFE9-07A9-4799-8562-34C79DE0DAB7Q27488307-22EF70E9-9210-4326-BF5A-2588C89BA681Q28577777-3D44028F-D303-4F9E-B22C-BF95850C82FDQ33714593-431A2608-6CBE-4FC6-8787-7DE0214B7997Q33782525-0590B195-49C7-4733-80E2-C343392FC9C5Q34979638-1FA45B65-4419-4169-8E4C-7D5306A82946Q35066350-4A8ADCD2-09A8-4169-9408-0C0984F07F58Q35073553-1DE54847-7C3F-4F93-8DDB-0654533ACF8CQ35077712-C74BFC00-87F3-4E9A-B6CE-154368A548EEQ35169059-01A5A12C-AC80-492E-9875-6DA2880B1D43Q35607785-4167E1D1-FEDD-47E8-A527-76DCA346EA39Q36236463-E369316C-A3D4-4483-8F96-77DE9C739D03Q36877307-0D81BE97-C764-488B-B418-B723466703E7Q37397265-102F112D-CCF4-444D-8270-55FF910A4AC0Q37693948-12CA3EB1-29DF-430F-BA63-16E9FD646CB3Q37834510-EC5776FC-C23B-4370-B993-A8A35CE3F860Q39471947-E61665E4-363D-4EF6-BDE3-046545DADC70Q39472205-57A049F3-6EF5-4A2C-831F-FB40B47CD4D0Q40567799-450711BD-48E0-4FEC-B763-772FB60A62ECQ40668772-18A05CD1-61D1-4890-B11A-DC95FA126AB4Q43047106-6DA58CC7-C755-4297-B324-174D521A5386Q43869933-843F4A86-9CC2-46A0-9E3F-03645328F7C5Q46049758-9572F70E-5F4A-46CC-BB2A-B89FC72050A9Q50576419-E8FFC3DB-FD49-4323-958D-59F8258E62D4Q57684855-1AD7BD63-4038-4B9B-9136-C83768097DF3
P2860
Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Intestinal absorption of ribav ...... oside purine (N1) transporter.
@en
Intestinal absorption of ribav ...... d by the Na+-nucleoside purine
@nl
type
label
Intestinal absorption of ribav ...... oside purine (N1) transporter.
@en
Intestinal absorption of ribav ...... d by the Na+-nucleoside purine
@nl
prefLabel
Intestinal absorption of ribav ...... oside purine (N1) transporter.
@en
Intestinal absorption of ribav ...... d by the Na+-nucleoside purine
@nl
P2093
P356
P1476
Intestinal absorption of ribav ...... oside purine (N1) transporter.
@en
P2093
P304
P356
10.1023/A:1011945103455
P50
P577
1998-06-01T00:00:00Z